Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

FATE US Equity

Fate Therapeutics IncHealth Care · Biological Products, (No Diagnostic Substances) · CIK 1434316 · FY ends Dec 31
$2.65
+0.09 (+3.52%)
USD · as of 2026-08-19 · marketstack
8 8-K filings · 1 13D · 2 13G
DateEventWhat happened / filerSource
2026-08-138-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-07-0813G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by BlackRock, Inc.sec.gov ↗
2026-06-158-K 5.07Submission of matters to a vote of security holderssec.gov ↗
2026-06-158-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
2026-06-048-K 8.01Other eventssec.gov ↗
2026-05-138-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-04-2313D/ASchedule 13D amendment — ≥5% beneficial owner (active intent) · by Redmile Group, LLCsec.gov ↗
2026-03-2613G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by VANGUARD GROUP INCsec.gov ↗
2026-02-268-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2025-11-138-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2025-10-278-K 8.01Other eventssec.gov ↗
2025-10-278-K 7.01Regulation FD disclosuresec.gov ↗
2025-10-148-K 7.01Regulation FD disclosuresec.gov ↗
2025-10-148-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2025-10-14

Every row is a filed document, checked against its EDGAR index.